Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes. Ophthalmology, 129(10), 1120-1128. 10.1016/j.ophtha.2022.05.019 (Original work published 2022)
. (2022). Susan Cotter
Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity. Journal Of The American Association For Pediatric Ophthalmology And Strabismus, 27(1), 10.e1-10.e8. 10.1016/j.jaapos.2022.11.020 (Original work published 2023)
. (2023). Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. Jama Ophthalmology, 138(6), 698-701. 10.1001/jamaophthalmol.2020.0334 (Original work published 2020)
. (2020). Relationship between clinical signs and symptoms of convergence insufficiency. Optometry And Vision Science , 90(9), 988-95. 10.1097/OPX.0000000000000012 (Original work published 2013)
. (2013). Symptoms in children with convergence insufficiency: before and after treatment. Optometry And Vision Science , 89(10), 1512-20. 10.1097/opx.0b013e318269c8f9 (Original work published 2012)
. (2012). Vision therapy/orthoptics for symptomatic convergence insufficiency in children: treatment kinetics. Optometry And Vision Science , 87(8), 593-603. 10.1097/OPX.0b013e3181e61bad (Original work published 2010)
. (2010). Validity of the convergence insufficiency symptom survey: a confirmatory study. Optometry And Vision Science , 86(4), 357-63. 10.1097/OPX.0b013e3181989252 (Original work published 2009)
. (2009).